Biotech Archives - Page 124 of 795

3 minute read

Abbott Announces First Global Procedures In A Clinical Trial Of Its Volt Pulsed Field Ablation System To Treat Patients With Abnormal Heart Rhythms

January 18, 10:01 AM

Abbott's Volt™ Pulsed Field Ablation System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillationPulsed field ablation – or PFA – uses high energy

ABT

2 minute read

XOMA Expands Its Commercial Royalty And Milestone Portfolio With DSUVIA Acquisition; Provided An $8M Non-Dilutive Royalty Capital Solution To Talphera

By Benzinga Newsdesk

January 18, 9:32 AM

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Department of

XOMA

4 minute read

Surrozen Provides Corporate Update On Clinical Programs; $43.4M In Cash, Cash Equivalents, And Marketable Securities As Of September 30, 2023 Resulting In Cash Runway Into 2025

By Benzinga Newsdesk

January 18, 9:31 AM

Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated HepatitisSZN-043- Completed enrollment for the Phase 1a clinical trial in chronic liver disease patients

SRZN

3 minute read

Korro Bio Highlights Data For Its Lead Program In Alpha-1 Antitrypsin Deficiency And Progress Across Its RNA Editing Portfolio

By Benzinga Newsdesk

January 18, 9:12 AM

KRRO-110 has a potentially best-in-class profile with secretion of ~50µM functional AAT protein after a single dose in a preclinical mouse modelEvidence of greater than 40% editing of SERPINA1 RNA in non-human primates

KRRO

4 minute read

Natera To Present New Data From The CIRCULATE-Japan And BESPOKE CRC Studies At ASCO GI 2024 Supporting Signatera’s Clinical Utility In CRC

By Benzinga Newsdesk

January 18, 9:07 AM

Oral presentations include updated 24-month DFS analysis from GALAXY and first interim analysis from BESPOKE CRCNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that new data on its

NTRA

3 minute read

Solta Medical’s Thermage FLX And TR-4 Return Pad Receive Registration Certifications In China

By Benzinga Newsdesk

January 18, 9:06 AM

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and Solta Medical, a global leader in the medical aesthetics market, today announced the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical

BHC

2 minute read

Enigma Biomedical Group USA Signs License Agreement With AbbVie For Novel 4R Tau PET Imaging Biomarkers

By Benzinga Newsdesk

January 18, 9:04 AM

Enigma Biomedical Group - USA (EBG-USA) today announced it has signed an exclusive license and option agreement with AbbVie for the development and potential commercialization of AbbVie's next-generation F18 PET imaging

ABBV

2 minute read

Vaxxinity Announces Collaboration On Space Medicine Research With University Of Central Florida

By Benzinga Newsdesk

January 18, 9:04 AM

Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The

VAXX

7 minute read

Lipocine And Verity Pharma Enter Into License Agreement For TLANDO Franchise In The U.S. And Canada; Lipocine To Receive $11M License Fee; Up To $259M In Development And Commercial Sales Milestones

By Benzinga Newsdesk

January 18, 9:03 AM

Lipocine to receive $11 million license feeUp to $259 million in development and commercial sales milestonesTiered royalties on net sales of licensed products up to 18%Commercialization of TLANDO transitions to Verity

LPCN

2 minute read

Spanish Healthcare Firm Grifols’ Reputational Damage and Debt Woes: European Central Bank Probes Lenders

By Vandana Singh

January 18, 8:33 AM

Explore ECB's inquiries into lenders amid accusations of financial manipulation by Gotham City Research. Grifols faces scrutiny over alleged debt misrepresentation, potentially impacting its leverage and financing costs.

GRFS